Theravance Biopharma, Inc.
TBPH
$14.30
$0.130.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.49% | 6.11% | 12.12% | 15.93% | 20.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.49% | 6.11% | 12.12% | 15.93% | 20.97% |
| Cost of Revenue | 14.40% | 14.59% | -7.33% | -23.40% | -27.77% |
| Gross Profit | 38.05% | -5.11% | 59.13% | 289.51% | 1,188.75% |
| SG&A Expenses | 9.71% | 4.10% | -1.81% | -6.75% | -7.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.35% | 7.67% | -3.83% | -13.42% | -16.03% |
| Operating Income | 9.37% | -9.98% | 20.90% | 38.23% | 43.36% |
| Income Before Tax | 204.85% | -30.02% | 9.45% | 30.46% | 42.91% |
| Income Tax Expenses | 263.96% | 31.68% | 99.26% | 258.88% | 601.04% |
| Earnings from Continuing Operations | 128.54% | -30.30% | -2.22% | 18.93% | 32.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 128.54% | -30.30% | -2.22% | 13.40% | -105.26% |
| EBIT | 9.37% | -9.98% | 20.90% | 38.23% | 43.36% |
| EBITDA | 9.76% | -12.66% | 19.89% | 38.21% | 43.24% |
| EPS Basic | 126.61% | -37.81% | -19.01% | -6.32% | -108.13% |
| Normalized Basic EPS | 213.79% | -27.49% | -0.75% | 21.85% | 26.38% |
| EPS Diluted | 125.20% | -37.91% | -19.10% | -6.41% | -108.14% |
| Normalized Diluted EPS | 211.61% | -27.49% | -0.75% | 21.85% | 26.38% |
| Average Basic Shares Outstanding | -0.29% | -4.81% | -11.75% | -18.34% | -24.27% |
| Average Diluted Shares Outstanding | -0.02% | -4.81% | -11.75% | -18.34% | -24.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |